Semaglutide, found in Novo Nordisk's Ozempic, may reduce Alzheimer's risk in type 2 diabetes patients, per new research. FDA considers banning compounded versions.
Published in Alzheimer’s & Dementia on Thursday, Oct. 24, the study found that semaglutide — the active ingredient in popular ...
The diabetes and weight loss drug Ozempic could lower the risk of Alzheimer’s disease among people with type 2 diabetes, ...